|
Vascular Endothelial Growth Factor Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors.
|
27989323 |
2017 |
|
Ischemic stroke
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Meta-Analysis of Genome-Wide Association Studies Identifies Genetic Risk Factors for Stroke in African Americans.
|
26089329 |
2015 |
|
Fasting blood glucose measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASDB |
Variants in MTNR1B influence fasting glucose levels.
|
19060907 |
2009 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
CDC5L knockdown inhibited tumor growth by down-regulating hTERT expression, and CDC5L was shown to be a transcriptional activator of hTERT in a luciferase reporter assay.
|
28472785 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Mutation of the polo-like kinase Cdc5, which functions in both the mitotic entry and mitotic exit pathways, is lethal in combination with overexpressed CKS1 Therefore we investigated the effect of targeting the human Cdc5 ortholog, PLK1, in breast cancers with various expression levels of human CKS1B Growth inhibition by PLK1 knockdown correlates with increased CKS1B expression in published tumor cell data sets, and this correlation was confirmed using shRNAs against PLK1 in tumor cell lines.
|
27558135 |
2016 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Cdc5L was highly expressed in HCC and significantly associated with multiple clinicopathological factors, including AJCC stage, tumor size, and Ki-67.
|
26553251 |
2016 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Prp19 Arrests Cell Cycle via Cdc5L in Hepatocellular Carcinoma Cells.
|
28387715 |
2017 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Our findings suggested that Cdc5L could play an important role in the tumorigenesis of HCC and thus be a potential therapeutical target to prevent HCC progression.
|
26553251 |
2016 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Besides, univariate and multivariate survival analyses demonstrated that high Cdc5L expression was an independent prognostic factor for HCC patients' poor survival.
|
26553251 |
2016 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Three genes (Notch2, H2AFY2, and CDC5L) showed similar expression differences between microsatellite instability and chromosomal instability cell lines as observed between the young and old cell cultures suggesting that they may play a role in tumorigenesis.
|
15574761 |
2004 |
|
myeloblastosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mutation of K100 significantly reduces the affinity of MoCdc5-DBD to a Cdc5-binding element but not to a conventional myeloblastosis (Myb) domain-binding element, suggesting that K100 is a key residue of the high binding affinity to Cdc5-binding element.
|
31652438 |
2019 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In summary, we have established the requirement of the CDC5L-AGRN circuit for the essential oncogenic role of NEAT1 in prostate cancer cells.<b>Significance:</b> An integrative methodology uncovers CDC5L-AGRN signaling as critical to the tumor-promoting function of long noncoding RNA NEAT1 in prostate cancer cells.<i>Cancer Res; 78(15); 4138-49.©2018 AACR</i>.
|
29871935 |
2018 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Oncogenic Properties of NEAT1 in Prostate Cancer Cells Depend on the CDC5L-AGRN Transcriptional Regulation Circuit.
|
29871935 |
2018 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Oncogenic Properties of NEAT1 in Prostate Cancer Cells Depend on the CDC5L-AGRN Transcriptional Regulation Circuit.
|
29871935 |
2018 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
In summary, we have established the requirement of the CDC5L-AGRN circuit for the essential oncogenic role of NEAT1 in prostate cancer cells.<b>Significance:</b> An integrative methodology uncovers CDC5L-AGRN signaling as critical to the tumor-promoting function of long noncoding RNA NEAT1 in prostate cancer cells.<i>Cancer Res; 78(15); 4138-49.©2018 AACR</i>.
|
29871935 |
2018 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Western blot and wound scratch analyses were used to determine the signaling pathway for CDC5L-mediated activation of CRC growth and migration.
|
28472785 |
2017 |
|
Colorectal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
CDC5L Promotes hTERT Expression and Colorectal Tumor Growth.
|
28472785 |
2017 |
|
melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CDC5L drives FAH expression to promote metabolic reprogramming in melanoma.
|
29371990 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
To some extent, our findings suggest that CDC5L may serve as a novel therapeutic target for human colorectal cancer.
|
28472785 |
2017 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mutation of the polo-like kinase Cdc5, which functions in both the mitotic entry and mitotic exit pathways, is lethal in combination with overexpressed CKS1 Therefore we investigated the effect of targeting the human Cdc5 ortholog, PLK1, in breast cancers with various expression levels of human CKS1B Growth inhibition by PLK1 knockdown correlates with increased CKS1B expression in published tumor cell data sets, and this correlation was confirmed using shRNAs against PLK1 in tumor cell lines.
|
27558135 |
2016 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
LHGDN |
To study the expression pattern of the target genes from the hotspot amplicon and known candidate genes from 6p12-21, we did quantitative reverse transcription-PCR analysis of MAPK14, MAPK13, CDKN1A, PIM1, MDGA1, BTB9, DNAH8, CCND3, PTK7, CDC5L, and RUNX2 on osteosarcoma patient samples and seven cell lines.
|
18567798 |
2008 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.
|
18567798 |
2008 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.
|
18567798 |
2008 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.
|
18567798 |
2008 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Utilizing tissue microarrays composed of normal esophageal squamous mucosa (n = 20), Barrett esophagus (n = 10), low-grade dysplasia (n = 14), high-grade dysplasia (n = 27), adenocarcinoma (n = 59), and node metastases (n = 27), we confirmed differential up-regulation of three proteins (Cdc2/Cdk1, Cdc5, and Igfbp3) in adenocarcinomas and Barrett lesions.
|
15725809 |
2005 |